Add as a preferred source on GoogleKiniksa Raises 2026 ARCALYST Revenue Outlook to $1.045 Billion-$1.050 Billion
Third-quarter ARCALYST net product revenue was $286 million, up about 58% from a year earlier. Kiniksa expects KPL-387 trial data in the second half of 2027.
Kiniksa Pharmaceuticals International, plc raised its 2026 net product revenue outlook for ARCALYST to $1.045 billion-$1.050 billion after third-quarter sales rose from a year earlier.
The new range replaces a prior forecast of $980 million-$995 million. ARCALYST net product revenue totaled $286 million in the third quarter, up from $180.9 million in the same period a year earlier, an increase of about 58%.
Kiniksa is enrolling and dosing patients in PASTORALE, a Phase 3 trial of KPL-387 for recurrent pericarditis. The company expects data from a pivotal KPL-387 trial in the second half of 2027.
Kiniksa expects to begin commercializing KPL-387 in 2028 or 2029.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.